Between December 2020 and February 2021, three drugmakers received Emergency Use Authorizations to distribute COVID-19 vaccines. The next step is a biologics license application—the technical name for full approval—a process Pfizer and Moderna have already begun. Experts from Penn are keeping a close eye on these regulatory steps, as well as the reporting mechanisms involved in assessing vaccine safety. The outlook thus far seems promising.
